Shari Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 3.60 Cr
as on 04-01-2025
- Paid Up Capital ₹ 1.23 Cr
as on 04-01-2025
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.25 Cr
as on 04-01-2025
- Revenue %
(FY 2022)
- Profit -1413.68%
(FY 2022)
- Ebitda 273.27%
(FY 2022)
- Net Worth 2.08%
(FY 2022)
- Total Assets 534.31%
(FY 2022)
About Shari Pharmachem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.60 Cr and a paid-up capital of Rs 1.23 Cr.
The company currently has active open charges totaling ₹5.25 Cr.
Raseshkumar Thakar, Jayeshchandra Ajaybharti, Hitesh Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U24110GJ2021PTC119842
- Company No.
119842
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jan 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Shari Pharmachem?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raseshkumar Thakar  | Director | 12-Feb-2023 | Current |
| Jayeshchandra Ajaybharti | Director | 30-Jan-2021 | Current |
Hitesh Patel  | Director | 04-Mar-2021 | Current |
| Ravechi Ajaybharti | Director | 30-Jan-2021 | Current |
Financial Performance of Shari Pharmachem.
Shari Pharmachem Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1413.68% decrease in profit. The company's net worth moved up by a moderate rise of 2.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shari Pharmachem?
In 2021, Shari Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sphere Specialty Chemicals Private LimitedActive 9 years 7 monthsRaseshkumar Thakar and Hitesh Patel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 Dec 2022 | ₹5.25 Cr | Open |
How Many Employees Work at Shari Pharmachem?
Shari Pharmachem has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shari Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shari Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
